Bernstein initiated coverage of Immunovant (IMVT) with a Market Perform rating and $28 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMVT:
- Undervalued Potential in Difficult-to-Treat RA: Buy Rating on Immunovant Driven by IMVT-1402’s Differentiated Profile and Underappreciated Market Opportunity
- Immunovant Rides Brepocitinib Momentum Into 2026
- Immunovant price target raised to $23 from $22 at Truist
- Immunovant price target raised to $44 from $41 at Guggenheim
- Advancing a Differentiated FcRn Pipeline: Late-Stage Catalysts and Solid Fundamentals Support Buy Rating on Immunovant